{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'erythematosus as well as other diseases) within 2 months or 5 half-lives prior to Visit 1, ,', 'whichever is longer.', 'E 09. Initiation of allergen immunotherapy within 3 months prior to Visit 1 or dose change from', '1 month prior to Visit 1 or a plan to begin allergen immunotherapy or to change its dose', 'during the Screening Period or the Randomized Treatment Period.', 'E 10. Exposure to another investigative antibody within a time period prior to Visit 1 that is less', 'than 5 half-lives of the antibody. In case the half-life is not known, then the minimum', 'interval since exposure to the prior investigative antibody is 6 months. The minimum', 'interval since exposure to any other (non-antibody) investigative study medication is', '30 days prior to Visit 1.', 'E 11. Patients receiving medications or therapy that are prohibited as concomitant medications', '(See Section 8.8.1).', 'E 12. Patients who have previously been treated in any clinical trial of dupilumab.', 'E', '13. Patients or his/her parent(s)/caregiver(s)/legal guardian(s) is related to the Investigator or', 'any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff thereof', 'directly involved in the conduct of the study.', '7.2.2 Exclusion Criteria Related to the Active Comparator and/or Mandatory Background', 'Therapies', 'E 14. Non-compliance with use of the mandatory background therapy (ie, medium-dose ICS', 'with a second controller medication [eg, LABA, LTRA, LAMA, or methylxanthines] or', 'high-dose ICS alone or high-dose ICS with second controller), during the Screening', 'Period, as defined as <80% of total number of prescribed doses of background medication', 'taken during the Screening Period. Compliance is verified based on background', 'medication use recorded on the patient electronic diary during the Screening Period.', 'E', '15. Patient treated with SCS for diagnoses other than severe exacerbation of asthma, and/or', 'high-potency topical steroids within 30 days before Screening Visit 1, during the Screening', 'Period, and/or during the randomized treatment phase of this study.', 'E 16. Patient with history of clinically significant renal, hepatic, cardiovascular, metabolic,', 'neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular or', 'other significant medical illness or disorder which, in the judgment of the Investigator,', 'could interfere with the study or require treatment that might interfere with the study.', 'Specific examples include but are not limited to uncontrolled diabetes, active hepatitis,', 'active or latent untreated tuberculosis, bronchiectasis. Patients with active tuberculosis,', 'latent untreated tuberculosis or a history of incompletely treated tuberculosis will be', 'excluded from the study unless it is well documented by a specialist that the patient has', 'been adequately treated and can now start treatment with a biologic agent, in the medical', 'judgment of the Investigator and/or infectious disease specialist. Tuberculosis testing will', 'be performed in every country according to their local guidelines as required by regulatory', 'Property of the Sanofi Group - strictly confidential', 'Page 46', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'authorities and/or ethic committees. Other conditions that are well controlled and stable', \"will not prohibit participation if deemed appropriate per the Investigator's judgment.\", '7.2.3 Exclusion Criteria Related to the Current Knowledge of Sanofi Compound', 'E 17. For female patients who have commenced menstruating at any time during the study and', 'are either:', 'Found to have a positive urine pregnancy test, or', 'Sexually active, not using an established acceptable contraceptive method:', '-', 'Oral, injected, inserted, or implanted hormonal contraceptive.', '-', 'Intrauterine device with or intrauterine system with progestogen.', '-', 'Barrier contraceptive (condom, diaphragm, or cervical/vault caps) used with', 'spermicide (foam, gel, film, cream, or suppository).', 'E 18. Diagnosed with active parasitic infection (helminthes); suspected or high risk of parasitic', 'infection, unless clinical and (if necessary) laboratory assessments have ruled out active', 'infection before randomization.', 'E 19. History of human immunodeficiency virus (HIV) infection or positive HIV serology at', 'Visit 1.', 'E', '20. Known or suspected history of immunosuppression, including history of invasive', 'opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis,', 'pneumocystosis, aspergillosis), despite infection resolution; or unusually frequent,', \"recurrent or prolonged infections, per Investigator's judgment.\", 'E 21. Evidence of acute or chronic infection requiring systemic treatment with antibacterials,', 'antivirals, antifungals, antiparasitics, or antiprotozoals within 4 weeks before Visit 1 or', 'during the Screening Period, significant viral infections within 4 weeks before Visit 1 or', 'during the Screening Period that may not have received antiviral treatment (eg, influenza', 'receiving only symptomatic treatment).', 'E', '22. Patients with active autoimmune disease or patients using immunosuppressive therapy for', 'autoimmune disease (eg, juvenile idiopathic arthritis, inflammatory bowel disease,', 'systemic lupus erythematosus) or patients with high titer autoantibodies at screening who', 'are suspected of having high risk for developing autoimmune disease at the discretion of', 'the Investigator or the Sponsor.', 'E', '23. Patient with a history of a systemic hypersensitivity reaction, other than localized injection', 'site reaction, to any biologic drug.', 'E 24. At any time: Patients with positive (or indeterminate) test for hepatitis B surface antigen', '(HBs-Ag); positive Immunoglobulin M (IgM) hepatitis B core antibody; positive total', 'hepatitis B core antibody (HBc-Ab) confirmed by positive hepatitis B virus DNA (HBV', 'Property of the Sanofi Group - strictly confidential', 'Page 47', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}